

## ASX Announcement

31 January 2023

# Quarterly Activities & Cash Flow Report

## Quarter ended 31 December 2022

**Sydney, Australia – 31 January 2023:** OncoSil Medical Ltd (ASX: OSL) (**OncoSil** or the **Company**), is pleased to provide an update on activities, for the quarter ending 31 December 2022. OncoSil is a medical device company that is commercialising its platform technology for the treatment of patients with locally advanced pancreatic cancer (LAPC) and seeking FDA approval for the OncoSil™ device to treat patients with bile duct cancer or distal cholangiocarcinoma (DCC).

### Key Highlights

- ✓ **Milestone of 10 patients being treated in Spain:** performed the implantation of the OncoSil™ device, resulting in the first 10 patients being treated within Spain;
- ✓ **OncoSil signs distribution agreement for selected Chinese markets:** OncoSil signed an agreement with Hind Wing Company Limited (Hind Wing), a company based in Hong Kong SAR provides exclusive distribution rights for the sale of the OncoSil™ device within the Hong Kong, Macao, The Greater Bay Area, China and the Hainan Special Economic Zone, China;
- ✓ **USA HDE for distal cholangiocarcinoma:** Currently in ongoing discussions with FDA; and
- ✓ **Cash position:** Cash balance of \$5.76 million as at 31 December 2022.

*All financial results in the attached 4C are in Australian dollars and are unaudited.*

### European Union and the United Kingdom

The team have continued to concentrate on assisting with local regulatory and ethics approvals for the OSPREY patient registry.

The Company has continued to work on several initiatives in preparation for market access, health insurance coverage and reimbursement applications in major European markets.

### Milestone of 10 patients being treated in Spain

Since treating the first patient in April 2022, four hospital sites have performed the implantation of the OncoSil™ device, resulting in the first 10 patients being treated within Spain. The sales team in Spain are continuing to activate additional hospital sites and will be continuing to work with existing sites for additional treatments in the coming months.

## OncoSil signs distribution agreement for selected Chinese markets

OncoSil signed an agreement with Hind Wing Company Limited (Hind Wing), a company based in Hong Kong SAR provides exclusive distribution rights for the sale of the OncoSil™ device within the Hong Kong, Macao, The Greater Bay Area, China and the Hainan Special Economic Zone, China.

Hind Wing was established in 1979 and provides distribution services for a broad range of pharmaceuticals, diagnostics, medical devices and over-the-counter healthcare products in Hong Kong, Macao and mainland China. Hind Wing has been granted the exclusive rights to distribute and promote the OncoSil device within the agreed territories during a three-year term.

## USA Humanitarian Device Exemption for distal cholangiocarcinoma

OncoSil continues to have an ongoing dialogue with the US Food and Drug Administration (FDA) in regard to its filed Humanitarian Device Exemption (HDE) application for its OncoSil™ device in the treatment of distal cholangiocarcinoma (DCC or bile duct cancer). A further meeting is scheduled early this year.

## Resignation of Prof. Ricky Sharma as Non-Executive Director

Prof. Ricky Sharma has informed the Board that he intends to step down from the Board of OncoSil effective 28 February 2023 due to increased time commitments from other responsibilities. The Board thanks Prof. Sharma for his valuable contribution to the Board and wish him all the best for the future.

## Corporate

As at 31 December 2022, OncoSil had a cash balance of \$5.76 million. During the Quarter, the Company's net cash used in operations was \$2.4 million, with \$0.65 million invested in R&D activities. Item 6.1 of the Appendix 4C relates to director fees and salaries paid in the quarter.

## Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

<b>Mr Nigel Lange</b> CEO & Managing Director E: <a href="mailto:nigel.lange@oncosil.com">nigel.lange@oncosil.com</a> T: +49 30 300 149 3043	<b>Mr Brian Leedman</b> Non-executive Director E: <a href="mailto:brian.leedman@oncosil.com">brian.leedman@oncosil.com</a> T: +61 (0) 412 281 780	<b>Mr Karl Pechmann</b> CFO & Company Secretary E: <a href="mailto:karl.pechmann@oncosil.com">karl.pechmann@oncosil.com</a> T: +61 2 9223 3344
---	--	---

## About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorus-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with the OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted six clinical studies with positive results on tolerability, safety and efficacy. CE Marking has been granted for the OncoSil™ device which can be marketed in the European Union and the United Kingdom. The OncoSil™ device has also been classified a Breakthrough Device in the European Union and the United Kingdom.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval.

In December 2018, the FDA granted Humanitarian Use Designation (HUD) for the OncoSil™ device for the treatment of unresectable bile duct cancer. In March 2020, the FDA granted Breakthrough Device Designation for the OncoSil™ for unresectable pancreatic cancer in conjunction with systemic chemotherapy.

Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$3b.

### **Forward Looking Statements**

This document contains certain forward-looking statements, relating to OncoSil's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. OncoSil Medical is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

**ONCOSIL MEDICAL LIMITED**

**ABN**

89 113 824 141

**Quarter ended ("current quarter")**

31 December 2022

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	69	202
1.2 Payments for		
(a) research and development	(647)	(1,409)
(b) product manufacturing and operating costs	(191)	(472)
(c) advertising and marketing	(117)	(203)
(d) leased assets	-	-
(e) staff costs	(1,486)	(2,803)
(f) administration and corporate costs	(826)	(1,675)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	821	821
1.8 Other (provide details if material)	-	-
<b>1.9 Net cash from / (used in) operating activities</b>	<b>(2,377)</b>	<b>(5,539)</b>

<b>2. Cash flows from investing activities</b>		
2.1 Payments to acquire:		
(a) entities	-	-
(b) businesses	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>-</b>	<b>-</b>

<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	150	150
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	(161)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>150</b>	<b>(11)</b>

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	7,953	11,280
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(2,377)	(5,538)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	150	(11)
4.5	Effect of movement in exchange rates on cash held	31	26
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>5,757</b>	<b>5,757</b>

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> <i>at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts</i>	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	5,757	7,953
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>5,757</b>	<b>7,953</b>

**6. Payments to related parties of the entity and their associates**

6.1 Aggregate amount of payments to related parties and their associates included in item 1

6.2 Aggregate amount of payments to related parties and their associates included in item 2

**Current quarter  
\$A'000**

66

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

**7. Financing facilities**

*Note: the term "facility" includes all forms of financing arrangements available to the entity.  
Add notes as necessary for an understanding of the sources of finance available to the entity.*

- 7.1 Loan facilities  
7.2 Credit standby arrangements  
7.3 Other (please specify)  
7.4 **Total financing facilities**

Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000

**7.5 Unused financing facilities available at quarter end**

- 7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	2,377
8.2 Cash and cash equivalents at quarter end (Item 4.6)	5,757
8.3 Unused finance facilities available at quarter end (Item 7.5)	-
8.4 Total available funding (Item 8.2 + Item 8.3)	5,757
8.5 <b>Estimated quarters of funding available (Item 8.4 divided by Item 8.1)</b>	2.42
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	

- 8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

- 8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

- 8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- 8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

31/01/2023

Date: .....

By the Board

Authorised by: .....

(Name of body or officer authorising release – see note 4)

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g., Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.